Equities

Carasent ASA

Carasent ASA

Actions
Health CareHealth Care Providers
  • Price (NOK)18.25
  • Today's Change0.300 / 1.67%
  • Shares traded125.56k
  • 1 Year change+36.60%
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Mar-24
  • 18-Apr-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in NOK

The 2 analysts offering 12 month price targets for Carasent ASA have a median target of 25.75, with a high estimate of 26.50 and a low estimate of 25.00. The median estimate represents a 43.06% increase from the last price of 18.00.
High47.2%26.50
Med43.1%25.75
Low38.9%25.00

Earnings history & estimates in NOK

On Feb 15, 2024, earnings of 0.158 per share. This result exceeded the -0.02 consensus loss of the one analyst covering the company
The next earnings announcement is expected on Oct 24, 2024.
Average growth rate+45.97%
Carasent ASA reported annual 2023 earnings of 0.143 per share on Feb 15, 2024.
Average growth rate+26.46%
More ▼

Revenue history & estimates in NOK

Carasent ASA had 2nd quarter 2024 revenues of 66.28m. This missed the 69.00m estimate of the one analyst following the company. This was 10.57% above the prior year's 2nd quarter results.
Average growth rate+1.74%
Carasent ASA had revenues for the full year 2023 of 243.98m. This was 24.95% above the prior year's results.
Average growth rate+22.97%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.